Skip to Content

Replimune Group Inc

Rating as of

Company Profile

Business Description

Replimune Group Inc is a clinical-stage biotechnology company. Its use proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. The company's pipeline products include RP1, RP2, and RP3.

18 Commerce Way
Woburn, MA, 01801
T +1 781 995-2443
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2019
Fiscal Year End Mar 31, 2020
Stock Type Distressed
Employees 104